¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary active transport"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active hyperemia
    ´Éµ¿ÃæÇ÷
  • active imagination
    Àû±Ø»ó»ó, Àû±Ø¸í»ó
  • active immunity
    ´Éµ¿¸é¿ª
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú, Ȱ¼ºÀç
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary hemostasis
    ÀÌÂ÷ÁöÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive transport
    ¼öµ¿¿î¹Ý
  • supersonic transport
    ÃÊÀ½ÆÄ¼ö¼Û
  • transport
    ¿î¹Ý
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý
  • transmembrane transport
    ¸·¿î¹Ý
  • secondary amenorrhea
    ÀÌÂ÷¹«¿ù°æ, ¼Ó¹ß¹«¿ù°æ
  • secondary aqueous
    Àç»ý¹æ¼ö, ÀÌÂ÷¹æ¼ö
  • secondary cardiomyopathy
    ÀÌÂ÷½ÉÀå±ÙÀ°º´Áõ
  • secondary constriction
    ÀÌÂ÷ÇùÂø
  • secondary contact
    ÀÌÂ÷Á¢ÃË
  • secondary culture
    µÎ¹øÂ°½É±â
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary disease
    ¼Ó¹ßº´
  • secondary dysmenorrhea
    ÀÌÂ÷¿ù°æÅë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Secondary ossification center
    ÀÌÂ÷»À¹ß»ýÁß½É
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÈ­Áß½É
  • Secondary ossification center [Epiphyseal ossification cente
    ÀÌÂ÷»À¹ß»ýÁ᫐ [»À³¡»À¹ß»ýÁß½É]
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÈ­Áß½É
  • Secondary bone trabecula
    ÀÌÂ÷»ÀÀܱâµÕ
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ¼ÒÁÖ
  • Secondary dentin
    ÀÌÂ÷»ó¾ÆÁú
    [¿¾ ¿ë¾î] ÀÌÂ÷»ó¾ÆÁú
  • Secondary nodule
    ÀÌÂ÷¼ÒÀý
    [¿¾ ¿ë¾î] ÀÌÂ÷¼ÒÀý
  • Secondary villus
    ÀÌÂ÷À¶¸ð
    [¿¾ ¿ë¾î] ÀÌÂ÷À¶¸ð
  • Secondary pregnancy
    ÀÌÂ÷ÀÓ½Å
    [¿¾ ¿ë¾î] ÀÌÂ÷ÀÓ½Å
  • Secondary spermatocyte
    ÀÌÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷Á¤¸ð¼¼Æ÷
  • Secondary spermatocyte
    ÀÌÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] Á¦ÀÌÁ¤¸ð¼¼Æ÷
  • Secondary nasal septum
    ÀÌÂ÷ÄÚÁß°Ý
    [¿¾ ¿ë¾î] ÀÌÂ÷ºñÁß°Ý
  • Secondary hair follicle
    ÀÌÂ÷ÅÐÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷¸ð³¶
  • Secondary sponge bone
    ÀÌÂ÷ÇØ¸é»À
    [¿¾ ¿ë¾î] ÀÌÂ÷ÇØ¸é°ñ
  • Secondary pulmonary lobule
    ÀÌÂ÷ÇãÆÄ¼Ò¿±
    [¿¾ ¿ë¾î] ÀÌÂ÷Æó¼Ò¿±
  • Palatine process [Secondary palate]
    ÀÔõÀåµ¹±â [ÀÌÂ÷ÀÔõÀå]
    [¿¾ ¿ë¾î] ±¸°³µ¹±â(ÀÌÂ÷±¸°³)
  • Lamellar membranous bone [Secondary membranous bone]
    ÃþÆÇ¸·»À [ÀÌÂ÷¸·»À]
    [¿¾ ¿ë¾î] ÀÌÂ÷¸·¼º°ñ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary ionization
    ÀÌÂ÷(ì£ó­) ÀÌ¿ÂÈ­(ûù)
  • secondary ion mass spectrometry
    ÀÌÂ÷ ÀÌ¿ÂÁú·®ºÐ±¤¹ý(ì£ó­òõÕáÝÂÎÃÛö)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • secondary lysosome
    ÀÌÂ÷(ì£ó­) ¶óÀ̼ҼØ
  • secondary malnutrition
    ÀÌÂ÷ ¿µ¾ç½ÇÁ¶(ì£ó­ç½å×ã÷ðà)
  • secondary messenger
    ÀÌÂ÷ Àü·É (ì£ó­îîÖµ)
  • secondary metabolite
    ÀÌÂ÷ ´ë»ç¹°(ì£ó­ÓÛÞóÚª)
  • secondary plant constituent
    ÀÌÂ÷ ½Ä¹°¼ººÐ(ì£ó­ãÕÚªà÷ÝÂ)
  • secondary plot
    ÀÌÂ÷(ì£ó­) Ç÷Ô
  • secondary protein derivative
    ÀÌÂ÷ ´Ü¹éÁúÀ¯µµÃ¼(ì£ó­Ó±ÛÜòõë¯Óôô÷)
  • secondary solvent
    ÀÌÂ÷ ¿ë¸Å(ì£ó­éÁØÚ)
  • secondary standard
    ÀÌÂ÷ Ç¥ÁØ(ì£ó­øöñÞ)
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
  • anion-transport protein
    À½À̿¿î¹Ý(ê¡Úõ) ´Ü¹éÁú(Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary tuberculosis
    ÀÌÂ÷¼º°áÇÙ
  • secondary X-ray
    ÀÌÂ÷X¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
CPSC congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission
HSH hypomagnesemia with secondary hypocalcemia
HSRD hypertension secondary to renal disease
LSSA lipid-soluble secondary antioxidant
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SIMS Secondary ion mass spectroscopy
SP Secondary progressive
ToF-SIMS Time of Flight Secondary Ion Mass Spectrometry
SE secondary electron
SHPT secondary hyperparathyroidism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active eruption
    Ȱ¼º ¸ÍÃâ, ´Éµ¿Àû ¸ÍÃâ
    1. ¸Å¸ôµÇ¾î ÀÖ´ø Ä¡¾Æ°¡ »ý¸®ÀûÀ¸·Î ´ëÇÕÄ¡ÀÇ ±³ÇÕ¸é±îÁö ¸ÍÃâÇϰųª ¸ÍÃâµÈ Ä¡¾Æ°¡ ¸¶¸ðµÈ °í°æ¸¸Å­ º¸»óÇϱâ À§ÇØ ¸ÍÃâÇÏ´Â Çö»ó. 2. Ä¡¾Æ°¡ ±³ÇÕÁ¢ÃËÀ» ÀÌ·é ÈÄ, ±³ÇÕÆò¸é ¹æÇâÀ¸·Î ´Éµ¿Àû À̵¿À» º¸ÀÌ´Â °Í.
  • active exercise program
    Àû±ØÀû ¿îµ¿
  • active gradient shielding
    ´Éµ¿ °æ»çÂ÷Æó
  • active hydrogen
    Ȱ¼º ¼ö¼Ò
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • active mandibular opening
    ´Éµ¿ ÇÏ¾Ç °³±¸
    ±æÇ×±Ù
  • active material
    Ȱ¼º ¹°Áú
    È­ÇÐ ¹ÝÀÀ¿¡ À־ Ã˸ÅÀÇ ¹ÝÀÀ ÃËÁø ´É·ÂÀ» Ȱ¼ºÈ­ ½ÃŰ´Â ¹°Áú.
  • active myofascial trigger point
    Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡
    ÃËÁøÀ» ÅëÇØ ÀÚ±ØÀ» ÁÖÁö ¾Ê´õ¶óµµ ±¹¼ÒÀûÀ̰ųª ÀüÀÌµÈ ÅëÁõÀ̳ª Áõ»óÀ» ³ªÅ¸³»´Â ±Ù¸· ¹ßÅëÁ¡.
  • active principle
    À¯È¿¼ººÐ
    ¾à¹°ÀÇ È¿°ú¸¦ ºÎ¿©ÇÏ´Â ¾à¹° ÁßÀÇ ¼ººÐ
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • active sensitization
    ´Éµ¿ °¨ÀÛ, ´Éµ¿Àû °¨ÀÛ
    »ýü¿¡ Ç׿øÀ» ÁÖ»çÇÑ °á°ú ³ªÅ¸³ª´Â ¿¹¹Î¼º.
  • active shimming
    ´Éµ¿ º¸Á¤
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ, Ȱµ¿¼º °áÇÙÁõ
    ȯÀÚ¿¡¼­ ±ÕÀÌ °ËÃâµÇ´Â »óÅ¿¡ ÀÖ´Â °áÇÙ.
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
channel transport <radiobiology> In inertial fusion research using light ion drivers, describes the use of current-carrying plasma channels (which are magnetically confined to the channel) to transport electron or ion beams between the ion diode and the fusion target. This allows the ion source to stand back from the target.
(09 Oct 1997)
reverse electron transport <chemistry> The energy-dependent movement of electrons against the thermodynamic gradient to form a strong reductant from a weaker electron donor.
(11 Jan 1998)
cholesterol ester transport proteins A protein that transports cholesterol esters from HDL to VLDL and LDL; a deficiency of this protein is associated with elevated HDL cholesterol.
(05 Mar 2000)
monosaccharide transport proteins Membrane transport proteins which bind glucose and sodium ions and enter the cell together. The sodium ions are then pumped out of the cell by a sodium potassium atpase. The rate and extent of the sugar transport depends on the sodium ion concentration. Inhibitors of the monosaccharide transport system are phlorizin, cytochalasin b, and inhibitors of the sodium potassium atpase system. Insulin increases the rate of monosaccharide transport across the membrane into the cell.
(12 Dec 1998)
cotranslational transport <cell biology> Process whereby a protein is moved across a membrane as it is being synthesised.
This process occurs during the translation of the message at membrane associated ribosomes in rough endoplasmic reticulum during the synthesis of secreted proteins in eukaryotic cells.
(18 Nov 1997)
coupled transport The linked, simultaneous transport of two substances across a cell membrane (or another intracellular membrane). If the two substances are moving in the same direction (both into the cell or both out of the cell) it is called symport. If the two substances are moving in opposite directions (one moves into the cell while the other moves out) it is called antiport.
(09 Oct 1997)
hydrogen transport The transfer of hydrogen from one metabolite (hydrogen donor) to another (hydrogen acceptor) through the action of an enzyme system; the donor is thus oxidised and the acceptor reduced.
(05 Mar 2000)
sperm transport Passive transport or active migration of spermatozoa from the testes through the male genital system as well as within the female genital system.
(12 Dec 1998)
nuclear transport <cell biology> Passage of molecules in and out of the nucleus, presumably via nuclear pores. Passage of proteins into the nucleus may depend on possession of a nuclear location sequence containing five consecutive positively charged residues PKKKRKV).
(18 Nov 1997)
nucleocytoplasmic transport <cell biology, molecular biology> Transport of molecules from the nucleus to the cytoplasm.
(18 Nov 1997)
iodide transport defect See: familial goiter.
(05 Mar 2000)
ion transport The movement of ions across energy-transducing cell membranes. Transport can be active or passive. Passive ion transport (facilitated diffusion) derives its energy from the concentration gradient of the ion itself and allows the transport of a single solute in one direction (uniport). Active ion transport is usually coupled to an energy-yielding chemical or photochemical reaction such as ATP hydrolysis. This form of primary active transport is called an ion pump. Secondary active transport utilises the voltage and ion gradients produced by the primary transport to drive the cotransport of other ions or molecules. These may be transported in the same (symport) or opposite (antiport) direction.
(12 Dec 1998)
orthograde transport Axonal transport from the cell body of the neuron towards the synaptic terminal. Opposite of retrograde transport and probably dependent on a different mechanochemical protein (almost definitely kinesin) interacting with microtubules.
(18 Nov 1997)
ovum transport Transport of the ovum or zygote from the site of ovulation to the site of implantation.
(12 Dec 1998)
electron transport The transport of electrons through a number of electron carriers in a set sequence.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypersonic transport
    ±ØÃÊÀ½¼Ó¼ö¼Û±â
  • mass transport
    (¹ö½º,ÀüÂ÷ µîÀÇ °ø°ø ¼ö¼Û ±â°ü¿¡ ÀÇÇÑ) ´ë·® ¼ö¼Û;´ë·® ¼ö¼Û ±â°ü
  • mechanical transport
    ÀÚµ¿Â÷ ºÎ´ë
  • transport
    ¼ö¼Û(±â,¼±,±â°ü);ȲȦ;µµÃë;¿­Áß;À¯Çü¼ö )
  • transport
    ¼ö¼ÛÇÏ´Ù;µµÃë(¿­Áß)ÄÉ ÇÏ´Ù;À¯Çü¿¡ óÇÏ´Ù;Á×ÀÌ´Ù
  • transport House
    ³ëµ¿´ç º»ºÎ
  • transport ship
    ¿î¼Û¼±
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á